4HAT
 
 | |
4HB0
 | | Crystal structure of CRM1 inhibitor Leptomycin B in complex with CRM1(K541Q,K542Q,R543S,K545Q,K548Q,K579Q)-Ran-RanBP1 | | Descriptor: | CHLORIDE ION, Exportin-1, GTP-binding nuclear protein Ran, ... | | Authors: | Sun, Q, Chook, Y.M. | | Deposit date: | 2012-09-27 | | Release date: | 2013-01-09 | | Last modified: | 2017-07-26 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
3OB1
 | |
3OB2
 | |
3PLF
 | | Reverse Binding Mode of MetRD peptide complexed with c-Cbl TKB domain | | Descriptor: | CALCIUM ION, CHLORIDE ION, E3 ubiquitin-protein ligase CBL, ... | | Authors: | Sun, Q, Sivaraman, J. | | Deposit date: | 2010-11-15 | | Release date: | 2010-12-01 | | Last modified: | 2023-12-06 | | Method: | X-RAY DIFFRACTION (1.92 Å) | | Cite: | An adjacent arginine, and the phosphorylated tyrosine in the c-Met receptor target sequence, dictates the orientation of c-Cbl binding
Febs Lett., 585, 2011
|
|
4GPT
 | | Crystal structure of KPT251 in complex with CRM1-Ran-RanBP1 | | Descriptor: | 1,2-ETHANEDIOL, 2-(2-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}ethyl)-1,3,4-oxadiazole, CHLORIDE ION, ... | | Authors: | Sun, Q, Chook, Y.M. | | Deposit date: | 2012-08-21 | | Release date: | 2012-09-05 | | Last modified: | 2013-01-23 | | Method: | X-RAY DIFFRACTION (2.22 Å) | | Cite: | Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Leukemia, 27, 2013
|
|
4HAX
 | |
4HAV
 | |
4HB2
 | | Crystal structure of CRM1-Ran-RanBP1 | | Descriptor: | 1,2-ETHANEDIOL, CHLORIDE ION, Exportin-1, ... | | Authors: | Sun, Q, Chook, Y.M. | | Deposit date: | 2012-09-27 | | Release date: | 2013-01-09 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
4HAU
 | |
4Q02
 | | Second-site screening of K-Ras in the presence of covalently attached first-site ligands | | Descriptor: | 3,4-difluorobenzenethiol, GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, ... | | Authors: | Sun, Q, Phan, J, Friberg, A, Camper, D.V, Olejniczak, E.T, Fesik, S.W. | | Deposit date: | 2014-03-31 | | Release date: | 2014-09-10 | | Method: | X-RAY DIFFRACTION (1.702 Å) | | Cite: | A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.
J.Biomol.Nmr, 60, 2014
|
|
4Q03
 | | Second-site screening of K-Ras in the presence of covalently attached first-site ligands | | Descriptor: | 4-bromobenzenethiol, GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, ... | | Authors: | Sun, Q, Phan, J, Friberg, A, Camper, D.V, Olejniczak, E.T, Fesik, S.W. | | Deposit date: | 2014-03-31 | | Release date: | 2014-09-10 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.201 Å) | | Cite: | A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.
J.Biomol.Nmr, 60, 2014
|
|
4PZY
 | | Second-site screening of K-Ras in the presence of covalently attached first-site ligands | | Descriptor: | 2-chloro-1-(1H-indol-3-yl)ethanone, GUANOSINE-5'-DIPHOSPHATE, K-Ras, ... | | Authors: | Sun, Q, Phan, J, Friberg, A, Camper, D.V, Olejniczak, E.T, Fesik, S.W. | | Deposit date: | 2014-03-31 | | Release date: | 2014-09-10 | | Method: | X-RAY DIFFRACTION (1.88 Å) | | Cite: | A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.
J.Biomol.Nmr, 60, 2014
|
|
4Q01
 | | Second-site screening of K-Ras in the presence of covalently attached first-site ligands | | Descriptor: | GUANOSINE-5'-DIPHOSPHATE, K-Ras, MAGNESIUM ION, ... | | Authors: | Sun, Q, Phan, J, Friberg, A, Camper, D.V, Olejniczak, E.T, Fesik, S.W. | | Deposit date: | 2014-03-31 | | Release date: | 2014-09-10 | | Method: | X-RAY DIFFRACTION (1.291 Å) | | Cite: | A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.
J.Biomol.Nmr, 60, 2014
|
|
4PZZ
 | | Second-site screening of K-Ras in the presence of covalently attached first-site ligands | | Descriptor: | 1H-benzimidazol-2-ylmethanethiol, GUANOSINE-5'-DIPHOSPHATE, K-Ras, ... | | Authors: | Sun, Q, Phan, J, Friberg, A, Camper, D.V, Olejniczak, E.T, Fesik, S.W. | | Deposit date: | 2014-03-31 | | Release date: | 2014-09-10 | | Method: | X-RAY DIFFRACTION (1.403 Å) | | Cite: | A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.
J.Biomol.Nmr, 60, 2014
|
|
6JL7
 | |
6JM5
 | | Crystal structure of TBC1D23 C terminal domain | | Descriptor: | SODIUM ION, TBC1 domain family member 23 | | Authors: | Sun, Q, Huang, W. | | Deposit date: | 2019-03-07 | | Release date: | 2019-10-16 | | Last modified: | 2024-03-27 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Structural and functional studies of TBC1D23 C-terminal domain provide a link between endosomal trafficking and PCH.
Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
5WY2
 | |
6KFT
 | | MVM NS2 mutant Nm42 in complex with CRM1-Ran-RanBP1 | | Descriptor: | 1,2-ETHANEDIOL, Exportin-1, GLYCEROL, ... | | Authors: | Sun, Q, Li, Y. | | Deposit date: | 2019-07-08 | | Release date: | 2020-07-15 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.51 Å) | | Cite: | Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Int J Nanomedicine, 16, 2021
|
|
6M6X
 | | Oridonin in complex with CRM1#-Ran-RanBP1 | | Descriptor: | (1beta,6beta,7beta,8alpha,9beta,10alpha,13alpha,14R,16beta)-1,6,7,14-tetrahydroxy-7,20-epoxykauran-15-one, 1,2-ETHANEDIOL, CHLORIDE ION, ... | | Authors: | Sun, Q, Lei, Y. | | Deposit date: | 2020-03-16 | | Release date: | 2021-03-17 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.88 Å) | | Cite: | Novel Mechanistic Observations and NES-Binding Groove Features Revealed by the CRM1 Inhibitors Plumbagin and Oridonin.
J.Nat.Prod., 84, 2021
|
|
6LQ9
 | | S109 in complex with CRM1-Ran-RanBP1 | | Descriptor: | (3~{R},4~{S})-1-[[6-chloranyl-5-(trifluoromethyl)pyridin-2-yl]amino]-3,4-dimethyl-pyrrolidine-2,5-dione, CHLORIDE ION, Exportin-1, ... | | Authors: | Sun, Q, Lei, Y. | | Deposit date: | 2020-01-13 | | Release date: | 2021-06-23 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
J.Med.Chem., 64, 2021
|
|
6M60
 | | Plumbagin in complex with CRM1#-Ran-RanBP1 | | Descriptor: | (2~{R})-2-methyl-5-oxidanyl-2,3-dihydronaphthalene-1,4-dione, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | | Authors: | Sun, Q, Lei, Y. | | Deposit date: | 2020-03-12 | | Release date: | 2021-06-09 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.17 Å) | | Cite: | Novel Mechanistic Observations and NES-Binding Groove Features Revealed by the CRM1 Inhibitors Plumbagin and Oridonin.
J.Nat.Prod., 84, 2021
|
|
6A3A
 | | MVM NES mutant Nm2 in complex with CRM1-Ran-RanBP1 | | Descriptor: | 1,2-ETHANEDIOL, Exportin-1, GLYCEROL, ... | | Authors: | Sun, Q, Li, Y. | | Deposit date: | 2018-06-15 | | Release date: | 2019-06-19 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Int J Nanomedicine, 16, 2021
|
|
6A3E
 | | MVM NES mutant Nm15 in complex with CRM1-Ran-RanBP1 | | Descriptor: | Exportin-1, GTP-binding nuclear protein Ran, GUANOSINE-5'-TRIPHOSPHATE, ... | | Authors: | Sun, Q, Li, Y. | | Deposit date: | 2018-06-15 | | Release date: | 2019-06-19 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Int J Nanomedicine, 16, 2021
|
|
6A3C
 | | MVM NES mutant Nm12 in complex with CRM1-Ran-RanBP1 | | Descriptor: | 1,2-ETHANEDIOL, CHLORIDE ION, Exportin-1, ... | | Authors: | Sun, Q, Li, Y. | | Deposit date: | 2018-06-15 | | Release date: | 2019-06-19 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.35 Å) | | Cite: | Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Int J Nanomedicine, 16, 2021
|
|
